The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 ...

Zepbound is the first medication approved to treat patients with obstructive sleep apnea, said Sally Seymour, the FDA's director of the division of pulmonology, allergy and critical care.

And as of December 20, Eli Lilly’s weight loss drug Zepbound (tirzepetide) has become the first prescription medication FDA-approved to treat obstructive sleep apnea by increasing airflow and ...

2017. Zepbound, an Eli Lilly drug, can now be prescribed to adults with “moderate-to-severe obstructive sleep apnea and obesity” to improve their sleep, a press release from the company said.